Form 4: Twist Bioscience Officer Sells Shares to Cover Tax Obligations

Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, sold 94 shares of common stock to cover tax withholding obligations related to Restricted Stock Unit vesting.

Summary

• Dennis Cho, an officer of Twist Bioscience Corp (TWST), specifically the Senior Vice President, Chief Legal Officer & Corporate Secretary, reported a transaction on June 16, 2025.
• The transaction involved the disposition (sale) of 94 shares of Twist Bioscience Common Stock at a price of $33.475 per share.
• This sale was explicitly stated to be a 'sell to cover' transaction, mandated by the Issuer's equity incentive plans to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units.
• The filing clarifies that these sales do not represent discretionary trades by Mr. Cho.
• Following this transaction, Dennis Cho beneficially owns 104,967 shares of Twist Bioscience Common Stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a non-discretionary 'sell to cover' for tax purposes, which is a routine event and does not indicate a positive or negative outlook from the insider.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• "Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units."
• "These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person."

Industry Context

This filing is a routine disclosure of an insider transaction, specifically a 'sell to cover' for tax purposes, which is a common occurrence across all industries for executives receiving equity compensation. It does not provide insights into broader industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: Minimal impact, as the sale is small (94 shares) and non-discretionary, not signaling a change in management's confidence.
• Employees: No direct impact mentioned, but it highlights the standard process for equity compensation and tax handling.

Key Dates

Keywords

Twist Bioscience, TWST, SEC Form 4, Insider Trading, Officer Transaction, Stock Sale, Restricted Stock Units, Tax Withholding, Equity Incentive Plan